{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:04:43Z","timestamp":1782486283082,"version":"3.54.5"},"reference-count":50,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacy"],"abstract":"<jats:p>This systematic integrative review evaluates the effectiveness of SGLT2 inhibitors in relation to improving glycaemic control, reducing cardiovascular events, and preserving renal function based on the latest published evidence. Search for publications referenced in PubMed, from January 2020 to January 2025, was conducted; 48 abstracts were reviewed, and 27 full-text articles were included for analysis\u2014systematic reviews, meta-analyses, narrative reviews and comparative effectiveness studies. SGLT2 inhibitors are effective in reducing glucose levels, but the magnitude of reduction varies compared to other classes of antidiabetics. A noticeable reduction in the risk of major cardiovascular events, cardiovascular and all-cause mortality was reported, particularly compared to DPP-4 inhibitors and placebo. SGLT2 inhibitors demonstrated the most pronounced and consistent benefits in reducing hospitalisation for heart failure among all other evaluated classes. However, outcomes like myocardial infarction and stroke results were inconsistent. Renal outcomes consistently favoured SGLT2 inhibitors in reducing the risk of acute kidney injury, slowing chronic kidney disease and lowering the risk of end-stage kidney disease. SGLT2 inhibitors provide consistent glucose-lowering, cardiovascular and renal benefits. However, heterogeneity in study designs, patient populations, and treatment durations does not allow drawing definitive conclusions and highlights the need for future research focused on conducting well-designed trials with standardised methodology.<\/jats:p>","DOI":"10.3390\/pharmacy14020047","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T08:26:19Z","timestamp":1773390379000},"page":"47","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness of SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Integrative Review of Reviews and Comparative Effectiveness Studies (2020\u20132025)"],"prefix":"10.3390","volume":"14","author":[{"given":"Desislava","family":"Stanimirova","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, Department of Organisation and Economy of Pharmacy, Medical University Sofia, 2 Dunav Street, 1431 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8116-5138","authenticated-orcid":false,"given":"Guenka","family":"Petrova","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Department of Organisation and Economy of Pharmacy, Medical University Sofia, 2 Dunav Street, 1431 Sofia, Bulgaria"},{"name":"Research Institute of Innovative Medical Science, Medical University Sofia, 2 Dunav Street, 1431 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zornitsa","family":"Mitkova","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Department of Organisation and Economy of Pharmacy, Medical University Sofia, 2 Dunav Street, 1431 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2022). Standards of Medical Care in Diabetes\u20142022. Diabetes Care, 45, S1\u2013S2.","DOI":"10.2337\/dc22-Sint"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Usman, M.S., Khan, M.S., and Butler, J. (2021). The interplay between diabetes, cardiovascular disease, and kidney disease. Chronic Kidney Disease and Type 2 Diabetes, American Diabetes Association.","DOI":"10.2337\/db20211-13"},{"key":"ref_3","unstructured":"International Diabetes Federation (2021). IDF Diabetes Atlas, International Diabetes Federation. [10th ed.]. Available online: https:\/\/diabetesatlas.org."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Fonseca-Correa, J.I., and Correa-Rotter, R. (2021). Sodium\u2013glucose cotransporter 2 inhibitors mechanisms of action: A review. Front. Med., 8.","DOI":"10.3389\/fmed.2021.777861"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.31083\/j.rcm.2018.02.907","article-title":"Cardiorenal outcomes in the CANVAS, DECLARE\u2013TIMI 58, and EMPA-REG OUTCOME trials: A systematic review","volume":"19","author":"Kluger","year":"2018","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/j.clinthera.2023.10.014","article-title":"SGLT-2 inhibitors to slow chronic kidney disease progression: A review","volume":"46","author":"Maxson","year":"2023","journal-title":"Clin. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s40264-020-01010-6","article-title":"Potential safety issues with use of sodium\u2013glucose cotransporter 2 inhibitors, particularly in people with type 2 diabetes and chronic kidney disease","volume":"43","author":"Milder","year":"2020","journal-title":"Drug Saf."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA\u2014A scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge","year":"2019","journal-title":"Res. Integr. Peer Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"62","DOI":"10.59556\/japi.71.0422","article-title":"GLP1i as a first-line antihyperglycemic in the management of type 2 diabetes in the context of Indians: A systematic review and consensus","volume":"71","author":"Singh","year":"2023","journal-title":"J. Assoc. Physicians India"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Teng, Y., Fan, X., Yu, R., and Yang, X. (2024). Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: A network meta-analysis. BMC Endocr. Disord., 24.","DOI":"10.1186\/s12902-024-01805-z"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s00125-024-06190-9","article-title":"Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes aged over 70 years: An instrumental variable approach","volume":"67","author":"Young","year":"2024","journal-title":"Diabetologia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40200-022-01004-4","article-title":"Real-world evaluation of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors for managing type 2 diabetes mellitus: A retrospective multi-ethnic cohort study","volume":"21","author":"Goh","year":"2022","journal-title":"J. Diabetes Metab. Disord."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/jamainternmed.2022.6664","article-title":"Comparing effectiveness and safety of SGLT2 inhibitors vs. DPP-4 inhibitors in patients with type 2 diabetes and varying baseline HbA1c levels","volume":"183","author":"Wexler","year":"2023","journal-title":"JAMA Intern. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"618","DOI":"10.7326\/M23-1490","article-title":"Newer pharmacologic treatments in adults with type 2 diabetes: A systematic review and network meta-analysis for the American College of Physicians","volume":"177","author":"Drake","year":"2024","journal-title":"Ann. Intern. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jacc.2024.06.016","article-title":"Kidney and cardiovascular effectiveness of SGLT2 inhibitors vs. GLP-1 receptor agonists in type 2 diabetes","volume":"84","author":"Edmonston","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/S2213-8587(23)00171-7","article-title":"Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: Emulation of a randomised target trial using electronic health records","volume":"11","author":"Xie","year":"2023","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"100847","DOI":"10.1016\/j.lanepe.2024.100847","article-title":"Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: A comparative effectiveness study on propensity score matched cohorts at low renal risk","volume":"38","author":"Fadini","year":"2024","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1007\/s13300-020-00930-x","article-title":"SGLT2 inhibitors: Slowing of chronic kidney disease progression in type 2 diabetes","volume":"11","author":"Wheeler","year":"2020","journal-title":"Diabetes Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1111\/dom.14474","article-title":"Comparative effectiveness and safety of sodium-glucose cotransporter-2 inhibitors versus metformin in patients with type 2 diabetes: An observational study using data from routine care","volume":"23","author":"Fralick","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Sinha, T., Gul, U., Babar, N.N., Israr, F., Butt, A.A., Chaudhari, S.S., Maqbool, H., and Amin, A. (2024). The comparison of the effectiveness of dapagliflozin and empagliflozin in the prevention of cardiovascular outcomes in patients with type 2 diabetes: A network meta-analysis. Cureus, 16.","DOI":"10.7759\/cureus.69711"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Kalluri, S.R., Bhutta, T.H., Hannoodee, H., Al Khalili, M., Theik, N.W.Y., Raji, O.E., Shenwai, P., Shah, R., and Khan, S. (2021). Do SGLT2 inhibitors improve cardio-renal outcomes in patients with type II diabetes mellitus: A systematic review. Cureus, 13.","DOI":"10.7759\/cureus.17668"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s13300-021-01004-2","article-title":"Sodium-glucose co-transporter 2 inhibitors (SGLT2i) exposure and outcomes in type 2 diabetes: A systematic review of population-based observational studies","volume":"12","author":"Caparrotta","year":"2021","journal-title":"Diabetes Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.2337\/dc20-1890","article-title":"Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of kidney outcomes: Emulation of a target trial using health care databases","volume":"43","author":"Xie","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1111\/dom.14741","article-title":"Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study","volume":"24","author":"Dong","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/dom.14598","article-title":"The comparative cardiovascular and renal effectiveness of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A Scandinavian cohort study","volume":"24","author":"Ueda","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/dom.15696","article-title":"Key results from observational studies and real-world evidence of sodium-glucose cotransporter-2 inhibitor effectiveness and safety in reducing cardio-renal risk","volume":"26","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12933-025-02592-0","article-title":"Association of sodium-glucose cotransporter-2 inhibitors with mortality across the spectrum of myocardial infarction: A systematic review and meta-analysis","volume":"24","author":"Maremmani","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Ahmed, M., Jain, H., Javaid, H., Ahsan, A., Szilagyi, S., Ahmad, A., and Ahmed, R. (2024). Efficacy of sodium-glucose cotransporter-2 inhibitors in patients with acute myocardial infarction: A meta-analysis of randomised controlled trials. Endocrinol. Diabetes Metab., 7.","DOI":"10.1002\/edm2.514"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/dom.14239","article-title":"Renal outcomes and all-cause death associated with sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL 3 Korea)","volume":"23","author":"Koh","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1111\/dom.14702","article-title":"Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network meta-analysis","volume":"24","author":"Cao","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/dom.15710","article-title":"A review of the latest real-world evidence studies in diabetic kidney disease: What have we learned about clinical practice and the clinical effectiveness of interventions?","volume":"26","author":"Bonnet","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_37","first-page":"211","article-title":"Comprehensive evaluation of the cardiovascular protective effects of sodium-glucose cotransporter 2 inhibitors in patients with advanced chronic kidney disease: A real-world evidence study","volume":"56","author":"Shiao","year":"2025","journal-title":"Am. J. Nephrol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/dom.14261","article-title":"Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based study","volume":"23","author":"Han","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Vizca\u00edno, V., D\u00edez-Fern\u00e1ndez, A., \u00c1lvarez-Bueno, C., Mart\u00ednez-Alfonso, J., and Cavero-Redondo, I. (2021). Safety and efficacy of SGLT2 inhibitors: A multiple-treatment meta-analysis of clinical decision indicators. J. Clin. Med., 10.","DOI":"10.3390\/jcm10122713"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamainternmed.2021.2488","article-title":"Comparative effectiveness of sodium-glucose cotransporter 2 inhibitors vs. sulfonylureas in patients with type 2 diabetes","volume":"181","author":"Xie","year":"2021","journal-title":"JAMA Intern. Med."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Xu, L., Wu, Y., Li, J., Ding, Y., Chow, J., Li, L., Liu, H., Wang, Z., Gong, T., and Li, Y. (2025). Efficacy and safety of 11 sodium-glucose cotransporter-2 inhibitors at different dosages in type 2 diabetes mellitus patients inadequately controlled with metformin: A Bayesian network meta-analysis. BMJ Open, 15.","DOI":"10.1136\/bmjopen-2024-088687"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"24695","DOI":"10.1038\/s41598-024-76256-6","article-title":"Model-based meta-analysis of HbA1c reduction across SGLT2 inhibitors using dose adjusted by urinary glucose excretion","volume":"14","author":"Sato","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Ma, H., Lin, Y.H., Dai, L.Z., Lin, C.S., Huang, Y., and Liu, S.Y. (2023). Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight\/obese patients with or without diabetes mellitus: A systematic review and network meta-analysis. BMJ Open, 13.","DOI":"10.1136\/bmjopen-2022-061807"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7812\/TPP\/22.137","article-title":"Use of SGLT2 inhibitors reduces heart failure and hospitalization: A multicenter, real-world evidence study","volume":"27","author":"Blanco","year":"2023","journal-title":"Perm. J."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Kongmalai, T., Tansawet, A., Pattanaprateep, O., Ratanatharathorn, C., Amornritvanich, P., Looareesuwan, P., Boonwatcharapai, B., Khunakorncharatphong, A., Nimitphong, H., and Srinonprasert, V. (2024). Can SGLT-2 inhibitors improve cardiovascular outcomes and ensure safety for patients with type 2 diabetes and heart failure in Thailand? A real-world multicentre retrospective cohort study. BMJ Open, 14.","DOI":"10.1136\/bmjopen-2024-090226"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"101032","DOI":"10.1016\/j.lanepe.2024.101032","article-title":"SGLT2 inhibitors for patients with type 2 diabetes mellitus after myocardial infarction: A nationwide observation registry study from SWEDEHEART","volume":"45","author":"Mohammad","year":"2024","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1038\/s41598-025-86172-y","article-title":"Real-world effectiveness and safety of sodium-glucose co-transporter 2 inhibitors in chronic kidney disease","volume":"15","author":"Hunsuwan","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: A systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_50","unstructured":"Higgins, J.P.T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M.J., and Welch, V.A. (2024). Cochrane Handbook for Systematic Reviews of Interventions, Cochrane. Available online: https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-10#section-10-10."}],"container-title":["Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2226-4787\/14\/2\/47\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T08:57:17Z","timestamp":1773392237000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2226-4787\/14\/2\/47"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":50,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["pharmacy14020047"],"URL":"https:\/\/doi.org\/10.3390\/pharmacy14020047","relation":{},"ISSN":["2226-4787"],"issn-type":[{"value":"2226-4787","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]}}}